Attached files

file filename
EX-32.1 - EX-32.1 - Baudax Bio, Inc.bxrx-ex321_9.htm
EX-31.2 - EX-31.2 - Baudax Bio, Inc.bxrx-ex312_8.htm
EX-31.1 - EX-31.1 - Baudax Bio, Inc.bxrx-ex311_10.htm
EX-23.1 - EX-23.1 - Baudax Bio, Inc.bxrx-ex231_289.htm
EX-10.29 - EX-10.29 - Baudax Bio, Inc.bxrx-ex1029_362.htm
EX-10.28 - EX-10.28 - Baudax Bio, Inc.bxrx-ex1028_191.htm
EX-10.27 - EX-10.27 - Baudax Bio, Inc.bxrx-ex1027_512.htm
EX-10.26 - EX-10.26 - Baudax Bio, Inc.bxrx-ex1026_229.htm
EX-10.25 - EX-10.25 - Baudax Bio, Inc.bxrx-ex1025_197.htm
10-K - 10-K - Baudax Bio, Inc.bxrx-10k_20191231.htm

Exhibit 5.1

 

 

3000 Two Logan Square

Eighteenth and Arch Streets

Philadelphia, PA  19103-2799

215.981.4000

Fax 215.981.4750

February 13, 2020

 

Board of Directors of Baudax Bio, Inc.

490 Lapp Road

Malvern, Pennsylvania 19355

 

RE:  Securities Registered under Registration Statement on Form S-3

Ladies and Gentlemen:

 

We are acting as counsel to Baudax Bio, Inc., a Pennsylvania corporation (the Company), in connection with the Companys issuance of up to $25,000,000 shares of the Companys common stock, par value $0.01 per share (the Shares), from time to time and at various prices in an at the market offering pursuant to that certain Sales Agreement, dated February 13, 2020 (the Agreement), by and between the Company and JMP Securities LLC (JMP). The Shares will be sold by the Company pursuant to the Companys registration statement on Form S-3 under the Securities Act of 1933, as amended (the Act), filed with the Securities and Exchange Commission (the Commission) on December 6, 2019 and declared effective by the Commission on December 16, 2019 (the Registration Statement), a base prospectus dated December 16, 2019 (the Base Prospectus) and a prospectus supplement dated February 13, 2020 (together with the Base Prospectus, the Prospectus). This opinion letter is furnished to you at your request to enable you to fulfill the requirements of Item 601(b)(5) of Regulation S-K, 17 C.F.R. § 229.601(b)(5), in connection with the issuance of the Shares.

 

For purposes of this opinion letter, we have examined copies of such agreements, instruments and documents as we have deemed an appropriate basis on which to render the opinions hereinafter expressed. In our examination of the aforesaid documents, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the accuracy and completeness of all documents submitted to us, the authenticity of all original documents, and the conformity to authentic original documents of all documents submitted to us as copies (including pdfs). As to all matters of fact, we have relied on the representations and statements of fact made in the documents so reviewed, and we have not independently established the facts so relied on. This opinion letter is given, and all statements herein are made, in the context of the foregoing.

 

This opinion letter is based as to matters of law solely on the Pennsylvania Business Corporation Law of 1988, as amended. We express no opinion herein as to any other statutes, rules or regulations.

        Philadelphia

Boston

Washington, D.C.

Los Angeles

New York

Pittsburgh

Detroit

Berwyn

Harrisburg

Orange County

Princeton

Rochester

Silicon Valley

Wilmington


www.pepperlaw.com

#56968293 v3


 

 

Baudax Bio, Inc.

Page 2

February 13, 2020

 

 

Based upon, subject to and limited by the foregoing, we are of the opinion that following: (i) issuance of the Shares pursuant to the terms of the Agreement and (ii) receipt by the Company of the consideration for the Shares specified in the resolutions of the Board of Directors, the Shares will be validly issued, fully paid, and nonassessable.

 

This opinion letter has been prepared for use in connection with the filing by the Company of an Annual Report on Form 10-K relating to the offer and sale of the Shares, which Form 10-K will be incorporated by reference into the Registration Statement and Prospectus, and speaks as of the date hereof. We assume no obligation to advise you of any changes in the foregoing subsequent to the delivery of this letter.

 

We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the above-described Annual Report on Form 10-K and to the reference to this firm under the caption Legal Matters in the Prospectus. In giving this consent, we do not thereby admit that we are an expert within the meaning of the Act.

 

Very truly yours,

/s/ PEPPER HAMILTON LLP

PEPPER HAMILTON LLP

 

 

#56968293 v3